NEXI
Q4 2026 EPS Estimate
$-12.88
Nov 17, 2026

Analyst Sentiment

Wall St. Consensus
Buy
4 analysts·Low coverage
63
Score
2 Buy (50%)2 Hold (50%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
250%
Hold
250%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$2.00
+1999900.0%
Consensus
$3.00
+2999900.0%
Bull
$5.00
+4999900.0%
12-Month Target Range4 analysts
$2.00$3.00$5.00
Current $0.00Consensus
Current Price
$0.00
Upside to Consensus
$3.00

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev
EPS
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027E
Revenue Avg
Low
High
EBITDA Avg
Low
High
EBIT Avg
Low
High
Net Income Avg$-1M$-1M
Low$-1M$-1M
High$-1M$-1M
EPS Avg$-1.01$-0.96
Low$-1.01$-0.96
High$-1.01$-0.96
Analysts (Rev / EPS) / 1 / 1
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027Q1 2028Q2 2028
Revenue Avg
Low
High
EBITDA Avg
Low
High
EBIT Avg
Low
High
Net Income Avg$-23M$-22M$-27M$-24M$-23M$-24M$-18M$-16M
Low$-23M$-22M$-27M$-24M$-23M$-24M$-18M$-16M
High$-23M$-22M$-27M$-24M$-23M$-24M$-18M$-16M
EPS Avg$-16.83$-16.08$-19.58$-17.58$-17.01$-17.41$-12.88$-11.63
Low$-16.83$-16.08$-19.58$-17.58$-17.01$-17.41$-12.88$-11.63
High$-16.83$-16.08$-19.58$-17.58$-17.01$-17.41$-12.88$-11.63
Analysts (Rev / EPS) / 1 / 1 / 1 / 1 / 1 / 1 / 1 / 1

Earnings Surprises

Recent Analyst Actions

Aug 16, 2022Barclays
Barclays Maintains Overweight on NexImmune, Lowers Price Target to $2
Target:$2.00
+68.1%from $1.19
Aug 16, 2022Raymond James
Raymond James Maintains Outperform on NexImmune, Lowers Price Target to $3
Target:$3.00
+138.1%from $1.26
Jun 1, 2022BTIG
BTIG Initiates Coverage On NexImmune with Buy Rating, Announces Price Target of $5
Target:$5.00
+119.3%from $2.28
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.